Cidara Therapeutics, Inc. Reports Net Loss of $8.2 Million for Q3 2023
Revenues Decline to $12.7 Million as Operating Expenses Increase
By NewsInMinutes
Published - Nov 02, 2023, 05:22 PM ET
Last Updated - Aug 28, 2024, 12:38 AM EDT
Cidara Therapeutics, Inc. (CDTX) has released its condensed cons olidated financial results for the third quarter of 2023, revealing a net loss of $8.2 million. The biotechnology company, specializing in the development of novel anti-infectives, reported a total revenue of $12.7 million for the three-month period ending September 30, 2023, reflecting a decrease from the same quarter in the previous year.
Net Income/Loss
Net Loss of $8.2 Million
Cidara Therapeutics, Inc. experienced a net loss of $8.2 million for the third quarter of 2023. This is a notable decline compared to the same period in 2022 when the company reported a net income of $14.9 million.
